Relay Therapeutics, Inc.

NasdaqGM:RLAY Stock Report

Market Cap: US$708.0m

Relay Therapeutics Future Growth

Future criteria checks 2/6

Relay Therapeutics's earnings are forecast to decline at 4.7% per annum while its annual revenue is expected to grow at 49.3% per year. EPS is expected to grow by 4.1% per annum. Return on equity is forecast to be -83.4% in 3 years.

Key information

-4.7%

Earnings growth rate

4.1%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate49.3%
Future return on equity-83.4%
Analyst coverage

Good

Last updated12 Dec 2024

Recent future growth updates

Recent updates

We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate

Dec 19
We're Keeping An Eye On Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate

Relay Therapeutics Has Interesting Science That Needs To Be Proven In Trials

Dec 01

Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations

Sep 11

Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Aug 03
Here's Why We're Not Too Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Situation

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Apr 17
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Relay Therapeutics: Platform More Important Than Programs

Mar 13

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Feb 13

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 21
Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Nov 14
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Jun 08
Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Feb 22
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Oct 23
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts

Sep 30

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Sep 18

Why did Relay Therapeutics stock drop today?

Sep 09

Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 02
Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Earnings and Revenue Growth Forecasts

NasdaqGM:RLAY - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202623-441-328-3598
12/31/20254-415-307-32512
12/31/202415-353-218-20812
9/30/202410-345-283-280N/A
6/30/202435-323-283-281N/A
3/31/202435-329-287-284N/A
12/31/202326-342-304-300N/A
9/30/202326-326-275-268N/A
6/30/20231-344-267-259N/A
3/31/20231-323-256-247N/A
12/31/20221-291-239-229N/A
9/30/20222-290-220-212N/A
6/30/20222-267-206-199N/A
3/31/20222-384-176-170N/A
12/31/20213-364-78-74N/A
9/30/202185-261-73-70N/A
6/30/202184-414-42-41N/A
3/31/202184-247-35-34N/A
12/31/202083-230-104-102N/A
9/30/2020N/A-289-92-90N/A
6/30/2020N/A-95-88-83N/A
3/31/2020N/A-86-84-78N/A
12/31/2019N/A-75-74-66N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RLAY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RLAY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RLAY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RLAY's revenue (49.3% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: RLAY's revenue (49.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RLAY is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 10:05
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Relay Therapeutics, Inc. is covered by 16 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Gaurav GoparajuBerenberg
Jason Matthew GerberryBofA Global Research